A double-blind, randomized, placebo-controlled, double-dummy, parallel group, fMRI [functional magnetic resonance imaging] study comparing BOLD activation patterns before and after 12 weeks of treatment with placebo, comparator and GW679769 [casopitant] in subjects with social anxiety disorder (SAD)

Trial Profile

A double-blind, randomized, placebo-controlled, double-dummy, parallel group, fMRI [functional magnetic resonance imaging] study comparing BOLD activation patterns before and after 12 weeks of treatment with placebo, comparator and GW679769 [casopitant] in subjects with social anxiety disorder (SAD)

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2008

At a glance

  • Drugs Casopitant (Primary)
  • Indications Social phobia
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Oct 2008 Trial phase changed from I/II to I as reported by ClinicalTrials.gov
    • 12 Oct 2008 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 02 Feb 2007 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top